Drosten Matthias, Hilken Gero, Böckmann Miriam, Rödicker Florian, Mise Nikica, Cranston Aaron N, Dahmen Uta, Ponder Bruce A J, Pützer Brigitte M
Department of Vectorology and Experimental Gene Therapy, University of Rostock, Schillingalle 70, D-18055 Rostock, Germany.
J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9. doi: 10.1093/jnci/djh226.
Dominant-activating mutations in the RET protooncogene, a receptor tyrosine kinase, have been identified as a cause of medullary thyroid carcinoma. Such oncogenic RET mutations induce its ligand-independent constitutive trans-autophosphorylation. We investigated the role of endogenous oncogenic RET autophosphorylation in maintaining the neoplastic phenotype in medullary thyroid carcinoma cells and orthotopic medullary thyroid carcinomas in RET transgenic mice.
We constructed adenoviral vectors expressing a dominant-negative truncated form of RET, termed RET(DeltaTK), and analyzed its effect on cell viability, apoptosis, and proliferation of TT medullary thyroid carcinoma cells. We investigated the effect of RET(DeltaTK) on downsteam signaling by assessing alterations in phosphorylation or in gene expression. The effect of RET(DeltaTK) in primary medullary thyroid carcinomas in transgenic mice was assessed by monitoring tumor growth. All statistical tests were two-sided.
Cell viability was reduced. Phosphorylation of Akt and extracellular signal-regulated kinase (ERK), components of downstream signal transduction pathways, was abolished, and cell cycle progression was reduced. Expression of cell cycle regulator cyclin D1 was decreased, and expression of cell cyle regulators p21(CIP1/WAF1) and p27(KIP1) was increased. Apoptosis was stimulated and concurrently the expression of BCL-2 was decreased. All in vitro experiments compared TT cells expressing RET(DeltaTK) with untreated control cells or control vector-treated cells. Furthermore, 2 weeks after injecting adenovirus-carrying RET(DeltaTK) into thyroid glands of transgenic mice with orthotopic medullary thyroid carcinoma, tumors were statistically significantly smaller than their initial size in mice treated with RET(DeltaTK) (43.6%, 95% confidence interval [CI] = 30.7% to 56.5%; P =.010; two-sided unpaired Student's t test), whereas tumors in mice treated with a control vector were larger than their initial size (139.8%, 95% CI = 120.3% to 159.3%; P<.001).
Selective disruption of oncogenic RET signaling in medullary thyroid carcinoma in vitro and in vivo is associated with loss of the neoplastic phenotype of medullary thyroid carcinoma and should be investigated further as the basis for new therapeutic approaches for this disease.
原癌基因RET作为一种受体酪氨酸激酶,其显性激活突变已被确认为甲状腺髓样癌的一个病因。此类致癌性RET突变可诱导其非配体依赖性组成型反式自磷酸化。我们研究了内源性致癌性RET自磷酸化在维持甲状腺髓样癌细胞和RET转基因小鼠原位甲状腺髓样癌的肿瘤表型中的作用。
我们构建了表达一种显性负性截短形式RET(称为RET(ΔTK))的腺病毒载体,并分析其对TT甲状腺髓样癌细胞的细胞活力、凋亡和增殖的影响。我们通过评估磷酸化或基因表达的改变来研究RET(ΔTK)对下游信号传导的影响。通过监测肿瘤生长来评估RET(ΔTK)对转基因小鼠原发性甲状腺髓样癌的作用。所有统计检验均为双侧检验。
细胞活力降低。下游信号转导途径的组成部分Akt和细胞外信号调节激酶(ERK)的磷酸化被消除,细胞周期进程减缓。细胞周期调节因子细胞周期蛋白D1的表达降低,而细胞周期调节因子p21(CIP1/WAF1)和p27(KIP1)的表达增加。细胞凋亡受到刺激,同时BCL-2的表达降低。所有体外实验均将表达RET(ΔTK)的TT细胞与未处理的对照细胞或对照载体处理的细胞进行比较。此外,将携带RET(ΔTK)的腺病毒注射到患有原位甲状腺髓样癌的转基因小鼠甲状腺中2周后,与用RET(ΔTK)处理的小鼠相比,肿瘤在统计学上显著小于其初始大小(43.6%,95%置信区间[CI]=30.7%至56.5%;P=0.010;双侧不成对学生t检验),而用对照载体处理的小鼠的肿瘤大于其初始大小(139.8%,95%CI=120.3%至159.3%;P<0.001)。
在体外和体内对甲状腺髓样癌中致癌性RET信号进行选择性破坏与甲状腺髓样癌肿瘤表型的丧失有关,应进一步研究以此作为该疾病新治疗方法的基础。